Cubist reiterated at strong buy by JMP

Cubist Pharmaceuticals, Inc. was reiterated at a strong buy by JMP Securities analyst Adam Cutler after a review of drivers and the competitive landscape for the company. The market for IV antibiotics is large, which is good news for Cubicin, the company's IV antibiotic approved for the treatment of complicated skin and skin structure infections, bacteremia and endocarditis. However, positive progress from potential Cubicin competitors (like Theravance's telavancin) could cause selling pressure on Cubist shares. Shares of the Lexington, Mass.-based biopharmaceutical company were down 29 cents, or 1.34%, at $20.69, on volume of 933,660 shares versus the three-month running average of 1,254,500 shares. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.